Notable Labs Company Description
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer.
The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment.
Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population.
The company’s pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia.
Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
It is in joint administration with Notable Labs, Inc.
| Country | Israel |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Kaile Zagger |
Contact Details
Address: 320 Hatch Drive Foster City, 94404 United States | |
| Phone | 415 851 2410 |
| Website | notablelabs.com |
Stock Details
| Ticker Symbol | NTBLQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0012002452 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kaile Zagger | Interim Chief Executive Officer and Chief Restructuring Officer |
| Scott Alan McPherson CFE, CPA, CVA | Chief Financial Officer |
| Dr. Joseph P. Wagner Ph.D. | Chief Scientific Officer |
| Dr. Glenn C. Michelson M.D. | Chief Medical Officer |